Redhill Biophrma ADR (RDHL)

$1.86 +0.04 (2.20%)
Market Cap 4.26M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 9,800
Avg Vol 262,734
Day's Range N/A - N/A
Shares Out 2.29M
Stochastic %K 62%
Beta 4.22
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
therealchorris
therealchorris Jun. 27 at 2:54 PM
$RDHL It has been awfully quiet on their X feed for 1.5 months now 🙄
0 · Reply
tatanka9
tatanka9 Jun. 26 at 11:35 PM
$RDHL RedSCAM!
0 · Reply
Michl2000
Michl2000 Jun. 26 at 3:06 PM
$RDHL all time chart -99.99% not bad 😁
0 · Reply
Michl2000
Michl2000 Jun. 26 at 1:57 PM
$RDHL tumbles from one low to another
1 · Reply
Balmus
Balmus Jun. 26 at 7:31 AM
$RDHL Number of outstanding shares: The percent of beneficial ownership for the Selling Shareholder is based on 2,295,345 ADSs outstanding as of June 24, 2025
0 · Reply
Balmus
Balmus Jun. 26 at 6:50 AM
$RDHL REDHILL BIOPHARMA LTD. 5,596,490 AMERICAN DEPOSITARY SHARES REPRESENTING 55,964,900,000 ORDINARY SHARES----https://d18rn0p25nwr6d.cloudfront.net/CIK-0001553846/60ce8af0-e0ae-4926-b662-0ba8dffe34f9.pdf
1 · Reply
Michl2000
Michl2000 Jun. 23 at 10:41 PM
$RDHL Great
0 · Reply
alexioj
alexioj Jun. 22 at 7:24 PM
$RDHL Tel Aviv's market rallied today:
0 · Reply
alexioj
alexioj Jun. 18 at 5:14 PM
$RDHL 1.70 area seems to attract buyers. Back to $2 next + hopefully we get some good news soon! ✌️
0 · Reply
Patrick2343
Patrick2343 Jun. 16 at 2:51 PM
$RDHL Simply amazing how god awful this stock is.
1 · Reply
Latest News on RDHL
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 6 weeks ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 2 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 2 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 2 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 2 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 2 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 3 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 3 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 4 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 4 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 5 months ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 5 months ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 7 months ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 7 months ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 8 months ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 8 months ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 9 months ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 9 months ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 9 months ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 10 months ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 10 months ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 10 months ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 10 months ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 10 months ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 11 months ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 11 months ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 11 months ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 11 months ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 11 months ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Apr 2, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Mar 11, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Mar 5, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

GILD

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Feb 20, 2024, 7:00 AM EST - 1 year ago

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

AMGN GILD

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Jan 26, 2024, 12:46 PM EST - 1 year ago

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

RedHill Biopharma Announces $8 Million Registered Direct Offering

Jan 25, 2024, 9:05 AM EST - 1 year ago

RedHill Biopharma Announces $8 Million Registered Direct Offering

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

Jan 25, 2024, 6:00 AM EST - 1 year ago

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

RedHill Biopharma shares jump as Ebola treatment shows promise

Dec 20, 2023, 9:13 AM EST - 1 year ago

RedHill Biopharma shares jump as Ebola treatment shows promise

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Dec 20, 2023, 8:45 AM EST - 1 year ago

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

Dec 4, 2023, 7:00 AM EST - 1 year ago

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

Nov 30, 2023, 9:33 AM EST - 1 year ago

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

AAPL ABBV AMC AMZN CRM DIS GME

RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!

Nov 28, 2023, 11:54 AM EST - 1 year ago

RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Nov 27, 2023, 7:00 AM EST - 1 year ago

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

Nov 14, 2023, 8:00 AM EST - 1 year ago

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

Oct 3, 2023, 7:00 AM EDT - 1 year ago

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

therealchorris
therealchorris Jun. 27 at 2:54 PM
$RDHL It has been awfully quiet on their X feed for 1.5 months now 🙄
0 · Reply
tatanka9
tatanka9 Jun. 26 at 11:35 PM
$RDHL RedSCAM!
0 · Reply
Michl2000
Michl2000 Jun. 26 at 3:06 PM
$RDHL all time chart -99.99% not bad 😁
0 · Reply
Michl2000
Michl2000 Jun. 26 at 1:57 PM
$RDHL tumbles from one low to another
1 · Reply
Balmus
Balmus Jun. 26 at 7:31 AM
$RDHL Number of outstanding shares: The percent of beneficial ownership for the Selling Shareholder is based on 2,295,345 ADSs outstanding as of June 24, 2025
0 · Reply
Balmus
Balmus Jun. 26 at 6:50 AM
$RDHL REDHILL BIOPHARMA LTD. 5,596,490 AMERICAN DEPOSITARY SHARES REPRESENTING 55,964,900,000 ORDINARY SHARES----https://d18rn0p25nwr6d.cloudfront.net/CIK-0001553846/60ce8af0-e0ae-4926-b662-0ba8dffe34f9.pdf
1 · Reply
Michl2000
Michl2000 Jun. 23 at 10:41 PM
$RDHL Great
0 · Reply
alexioj
alexioj Jun. 22 at 7:24 PM
$RDHL Tel Aviv's market rallied today:
0 · Reply
alexioj
alexioj Jun. 18 at 5:14 PM
$RDHL 1.70 area seems to attract buyers. Back to $2 next + hopefully we get some good news soon! ✌️
0 · Reply
Patrick2343
Patrick2343 Jun. 16 at 2:51 PM
$RDHL Simply amazing how god awful this stock is.
1 · Reply
cryptoish
cryptoish Jun. 14 at 2:19 AM
$RDHL they are good at nuking both countries and charts
0 · Reply
Michl2000
Michl2000 Jun. 14 at 12:57 AM
$RDHL Unlike often before it seems that this time they are only affected by the current political escalation.
0 · Reply
Michl2000
Michl2000 Jun. 13 at 2:10 PM
$RDHL all time low - great!
1 · Reply
Michl2000
Michl2000 Jun. 13 at 1:50 PM
$RDHL sell and get lucky
0 · Reply
Michl2000
Michl2000 Jun. 13 at 1:48 PM
$RDHL running down :-)
0 · Reply
tatanka9
tatanka9 Jun. 13 at 12:54 AM
$RDHL
0 · Reply
alexioj
alexioj Jun. 12 at 10:35 PM
$RDHL 🧐
0 · Reply
alexioj
alexioj Jun. 11 at 3:15 PM
$RDHL Golden Cross on the 1-hour chart coming soon:
1 · Reply
alexioj
alexioj Jun. 9 at 9:17 PM
$RDHL Running soon? 🧐
0 · Reply
therealchorris
therealchorris Jun. 9 at 6:01 PM
$RDHL Wow, back over $2 😁🙄
0 · Reply
alexioj
alexioj Jun. 9 at 6:00 PM
$RDHL There is now a clear breakout on the 1-day chart:
0 · Reply
alexioj
alexioj Jun. 9 at 3:38 PM
$RDHL Added. Nice to see $2 again!
0 · Reply